Search clinical trials for: Percutaneous Isolated Limb Perfusion (PILP) delivery

Total 14 results

Vastra Gotaland Region

Recruiting

Minimally-Invasive Isolated Limb Perfusion (MI-ILP)

Isolated Limb Perfusion

Sweden
Osprey Medical, Inc

Completed

Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients

Diabetes | Infection

Australia
Philogen S.p.A.
Eudax S.r.l.; InnoPharma Inc.

Completed

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Patients With Intransit Stage III/IV Melanoma

Italy
Vastra Gotaland Region

Recruiting

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (NivoILP)

Melanoma | In-Transit Metastasis

Sweden, Netherlands
Emilia Bagiella
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Hybrid Coronary Revascularization Trial

Coronary Artery Disease

United States, Canada
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

Recurrent Melanoma | Stage IV Melanoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Stage IIIB Melanoma | Stage IIIC Melanoma | Basal Cell Carcinoma of the Skin | Eccrine Carcinoma...

United States
National Cancer Institute (NCI)

Completed

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

Melanoma

United States
Delcath Systems Inc.

Active, not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
National Cancer Institute (NCI)

Completed

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

Melanoma | Sarcoma

United States
University of Miami

Completed

Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Sarcoma

United States
National Cancer Institute (NCI)

Completed

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

Recurrent Melanoma | Stage III Melanoma

United States
Delcath Systems Inc.

Terminated

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

Germany
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Sarcoma | Melanoma (Skin)

United States
Delcath Systems Inc.

Withdrawn

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

Hepatocellular Carcinoma (HCC)

United States

Search clinical trials for: Percutaneous Isolated Limb Perfusion (PILP) delivery

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations